TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03432624

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum MicroRNA-25 detection
Description: The level of microRNA-25 in serum of patients will be detected using the MicroRNA (microRNA-25) Qualitative Detection Kit (Fluorescent PCR Method) and following the manufacture's instruction.\*all arms are given the same intervention.

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum MicroRNA-25 detection
Description: The level of microRNA-25 in serum of patients will be detected using the MicroRNA (microRNA-25) Qualitative Detection Kit (Fluorescent PCR Method) and following the manufacture's instruction.\*all arms are given the same intervention.

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum MicroRNA-25 detection
Description: The level of microRNA-25 in serum of patients will be detected using the MicroRNA (microRNA-25) Qualitative Detection Kit (Fluorescent PCR Method) and following the manufacture's instruction.\*all arms are given the same intervention.

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum MicroRNA-25 detection
Description: The level of microRNA-25 in serum of patients will be detected using the MicroRNA (microRNA-25) Qualitative Detection Kit (Fluorescent PCR Method) and following the manufacture's instruction.\*all arms are given the same intervention.

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum MicroRNA-25 detection
Description: The level of microRNA-25 in serum of patients will be detected using the MicroRNA (microRNA-25) Qualitative Detection Kit (Fluorescent PCR Method) and following the manufacture's instruction.\*all arms are given the same intervention.
Study: NCT03408158

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: same type infusion of main HPA antigen
Description: Compare the differences of platelet count between participants with same type infusion of main HPA antigen and not
Study: NCT00966641

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Single orally administered dose of 500 mg naproxen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PL 3100
Description: Single orally administered dose of PL 3100 (500 mg naproxen)
Study: NCT01876823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: es-citalopram
Description: es-citalopram 10mg/day will be given for the first week, and 20mg/day starting at week 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: After two weeks on Lexapro, Memantine 5mg will be added. The dose will increase to 10mg for the second week and will be increased at a rate of 5mg per week. Memantine dosage will not exceed 20mg.
Study: NCT02738177

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 2 tablets of misoprostol (i.e. 400 ug) 4 hrs prior to surgical evacuation high up in the posterior fornix (misoprostol group)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide-5-mononitrate
Description: 2 tablets of Effox (i.e. 40 mg) 4 hrs prior to surgical evacuation high up in the posterior fornix (effox group)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol and Isosorbide-5-mononitrate
Description: 1tablets of misoprostol (i.e.200 ug) \& 1 tablets of Effox (i.e. 20 mg) 4 hrs prior to surgical evacuation high up in the posterior fornix (combination therapy group)
Study: NCT00142480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given orally for 14 consecutive days (days 1-14) followed by a week of no capecitabine then another week of 14 consecutive days (days 21-28).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given intravenously once weekly during weeks 1, 2, 4 and 5 on days 1, 8, 22 and 29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given intravenously every two weeks during weeks 1, 3 and 5 on days 1, 15 and 29.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Once daily for 5 days (Monday through Friday) for a total of 28 treatments.
Study: NCT04639453

Intervention type: DIAGNOSTIC_TEST
Intervention: Trunk strength with hand-held dynamometer
Description: MicroFET 2 Handheld Dynamometer is a force evaluation testing device to evaluate the strength of various trunk muscle groups in flexion, extension, and lateral (N).

Intervention type: DIAGNOSTIC_TEST
Intervention: Balance Assessment in Sitting and Standing test (BASS)
Description: The BASS is a test to assess static and dynamic sitting and standing balance, which has been validated for post-stroke hemiparetic patients. Each test is evaluated by a score from 0 (patient needs external support) to 4 (stable without external help) for static condition and from 0 (no possibility to pick up objects) to 3 (objects picked up without external help) for dynamic condition. The maximal score (sitting, standing, static and dynamic) is 14 points.

Intervention type: DIAGNOSTIC_TEST
Intervention: Timed Up and Go test
Description: The participant sits on a chair, gets up, walks 3m, makes a half turn in 1m2, walks 3m and comes back to sit on the chair. The time (s) to complete the task is measured.

Intervention type: DIAGNOSTIC_TEST
Intervention: Modified Functional Reach Test (MFRT)
Description: The MFRT is a dynamic seated balance test that measures the trunk's ability to move forward, to the paretic and non paretic side (cm).

Intervention type: DIAGNOSTIC_TEST
Intervention: Joint Position sense test (trunk)
Description: The joint positional sense test of the trunk consists in evaluating the positional error of the trunk in the sagittal plane (mm) and in the frontal plane (mm) during a trunk flexion posture (target position).

Intervention type: DIAGNOSTIC_TEST
Intervention: Unstable sitting in a seesaw
Description: This test evaluates the balance capacities of the subject in an unstable sitting position on a seesaw (mediolateral or anteroposterior instability) with forceplate and phone application using center of pressure variables: total displacement (mm), area (mm2), deltas (mm), mean velocity (mm/s) et maximal velocity (mm/s).
Study: NCT03948776

Intervention type: DIAGNOSTIC_TEST
Intervention: BodyMetrix body composition ultrasound
Description: Investigators will make ultrasound measurements of fat and muscle thickness at 7 positions on the arm, chest wall, and leg (subject's dominant side) using the BodyMetrix BX 2000 ultrasound machine. Clear ultrasound gel will be applied to the skin, a probe placed against the skin, and the fat/muscle thickness measurement made five times at each position. The gel is then wiped away. The images are analyzed by the BodyView Software and estimations of fat and muscle mass calculated. These will be compared to the reference technique of whole-body DXA imaging.

Intervention type: DIAGNOSTIC_TEST
Intervention: BodyMetrix body composition ultrasound
Description: Investigators will make ultrasound measurements of fat and muscle thickness at 7 positions on the arm, chest wall, and leg (subject's dominant side) using the BodyMetrix BX 2000 ultrasound machine. Clear ultrasound gel will be applied to the skin, a probe placed against the skin, and the fat/muscle thickness measurement made five times at each position. The gel is then wiped away. The images are analyzed by the BodyView Software and estimations of fat and muscle mass calculated. These will be compared to the reference technique of whole-body DXA imaging.

Intervention type: DIAGNOSTIC_TEST
Intervention: BodyMetrix body composition ultrasound
Description: Investigators will make ultrasound measurements of fat and muscle thickness at 7 positions on the arm, chest wall, and leg (subject's dominant side) using the BodyMetrix BX 2000 ultrasound machine. Clear ultrasound gel will be applied to the skin, a probe placed against the skin, and the fat/muscle thickness measurement made five times at each position. The gel is then wiped away. The images are analyzed by the BodyView Software and estimations of fat and muscle mass calculated. These will be compared to the reference technique of whole-body DXA imaging.

Intervention type: DIAGNOSTIC_TEST
Intervention: BodyMetrix body composition ultrasound only
Description: Investigators will make ultrasound measurements of fat and muscle thickness at 7 positions on the arm, chest wall, and leg (subject's dominant side) using the BodyMetrix BX 2000 ultrasound machine. Clear ultrasound gel will be applied to the skin, a probe placed against the skin, and the fat/muscle thickness measurement made five times at each position. The gel is then wiped away. The images are analyzed by the BodyView Software and estimations of fat and muscle mass calculated. For inpatients currently admitted to the hospital, whole-body DXA imaging cannot be performed, as so the only assessment of body composition will be with the ultrasound.
Study: NCT05170373

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESP block
Description: Before general anesthesia, ESP block was applied from the T12 vertebra level with 10 ml 0.5% bupivacaine HCL 5 ml 2% lidocaine HCL 5 ml 0.9% isotonic NaCl mixture
Study: NCT04287023

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: individual physical therapy
Description: cardiovascular warm-up activities, stretching exercises, strengthening exercises, functional, gait and balance training, recreational games and ended with relaxation exercises - individual
Study: NCT04060641

Intervention type: GENETIC
Intervention: Geneticure for RDN Genetic Panel
Description: This retrospective trial will include the collection of DNA using buccal swabs and the assessment of 22 genotypes for scoring to assess response to renal denervation
Study: NCT02626689

Intervention type: OTHER
Intervention: Quality of Life (QOL) questionnaires
Description: Monitoring of FACT-AN, SF-36V2, TransQol, and NTD PRO assessments,

Intervention type: OTHER
Intervention: Quality of Life (QOL) questionnaires
Description: Monitoring of FACT-AN, SF-36V2, TransQol, and NTD PRO assessments,

Intervention type: OTHER
Intervention: Healthcare Resource Utilization
Description: Monitoring and reviewing HealthCare Resource Utilization information.
Study: NCT04287023

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: group physical therapy
Description: cardiovascular warm-up activities, stretching exercises, strengthening exercises, functional, gait and balance training, recreational games and ended with relaxation exercises - groups of 10 patients
Study: NCT04250272

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracoscopic lobectomy
Description: Thoracoscopic lobectomy was performed for lung cancer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracoscopic lobectomy
Description: Thoracoscopic lobectomy was performed for lung cancer
Study: NCT02626689

Intervention type: OTHER
Intervention: Healthcare Resource Utilization
Description: Monitoring and reviewing HealthCare Resource Utilization information.
Study: NCT00170950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1
Description: Benazepril hydrochloride (HCl)/amlodipine besylate 10/5 mg capsules for oral administration once daily.
Study: NCT01664494

Intervention type: DRUG
Intervention: Capecitabine
Description: Capecitabine will be given according to the label text as monotherapy (1250 mg/m\^2 twice daily) or combination therapy (800 to 1000 mg/m\^2 or 1250 mg/m\^2 twice daily) for 14 consecutive days followed by a treatment break of 7 days.
Study: NCT00212771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asenapine
Description: Flexible dose, 1-2 tablets sublingual two times per day (1 or 2 tablets in the morning and 1 or 2 tablets in the evening). Each tablet contains either 5 mg asenapine or matching placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: Flexible dose, 1-2 capsules oral once per day (in the morning). Each capsule contains 10 mg olanzapine or matching placebo.
Study: NCT03392961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-105 (Insulin Tregopil)
Description: 15 mg strength tablets for oral use used at a dose of 30 mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo tablet for oral use
Study: NCT00058617

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of EBV Specific CTLs
Description: Each patient will receive two injections, 14 days apart, according to the following dosing schedules:~Group One Day 0 2x10\^7 cells/m2 Day 14 2x10\^7 cells/m2~Group Two Day 0 2x10\^7 cells/m2 Day 14 1x10\^8 cells/m2~Group Three Day 0 1x10\^8 cells/m2 Day 14 2x 10\^8 cells/m2~If patients with active disease have stable disease or a partial response by the RECIST criteria at their 8 week or subsequent evaluations they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number as their second injection. Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion.
Study: NCT04366466

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: suicide attempt patient using PEPS Program
Description: The research protocol consists of two phases separated by randomization.~A Hospital Phase common to both groups:~Day zero is the day of the suicide attempt for which the patient came to the hospital.~A post-hospital phase including the P.E.P.S. program for the intervention group and telephone reminders for the usual treatment group.

Intervention type: OTHER
Group type: OTHER
Intervention: suicide attempt patient using PEPS Program
Description: The research protocol consists of two phases separated by randomization.~A Hospital Phase common to both groups:~Day zero is the day of the suicide attempt for which the patient came to the hospital.~A post-hospital phase including the P.E.P.S. program for the intervention group and telephone reminders for the usual treatment group.
Study: NCT02248337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colon preparation for colonoscopy
Description: Colon cleansing prior to perform colonoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colon preparation for colonoscopy
Description: Colon cleansing prior to perform colonoscopy
Study: NCT01373892

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Study: NCT02332135

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microwave ablation
Description: First, the investigators detect the iPTH levels of all the patients in the investigators' blood purification center. The patients whose iPTH are between 300pg/ml and 800pg/ml and who have parathyroid nodular or diffuse hyperplasia demonstrated on ultrasound imaging or radioisotope scan are chosen to involve in this study. Patients are divided into 2 groups at random, the control group and the microwave ablation group. In the microwave ablation group, patients will accept microwave ablation. Oral medicines, if needed, will be taken according to the the suggestions in K/DOQI guideline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: active vitamin D
Description: The control group will be treated by active vitamin D and other general treatment,such as dietary phosphate restriction and phosphate binders,according to the suggestions in K/DOQI guideline.
Study: NCT01835132

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gevokizumab
Description: Subcutaneous injection of 60 mg gevokizumab
Study: NCT01684722

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D3 (cholecalciferol), 2000 IU per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D3 (cholecalciferol), 2000 IU per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acids (fish oil)
Description: Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acids (fish oil)
Description: Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D placebo
Description: Vitamin D3 placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D placebo
Description: Vitamin D3 placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil placebo
Description: Fish oil placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish oil placebo
Description: Fish oil placebo
Study: NCT04379661

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online support Group
Description: 12 one-hour, once-weekly online support groups for people with Multiple Sclerosis to address anxiety related to the COVID-19 outbreak and its effects on them.
Study: NCT03773094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guava leaves extract
Description: Natural product : The leaves of the guava tree are full of antioxidants, anti-inflammatory agents, antibacterials, and even tannins that can have significant health benefits, from treating stomach troubles to chronic diseases like cancer~•

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: chemical agent used as a mouthwash against cariogenic bacteria. considered the gold standard
Study: NCT03426319

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular evaluation
Description: Cardiovascular evaluation includes anamnesis, physical examination, laboratory tests, analysis of endothelial function, 24h blood pressure profile, Holter ECG, echocardiography and cardiac MRI.
Study: NCT03815357

Intervention type: OTHER
Intervention: Referral to Immunology
Description: Screening for primary immunodeficiency including splenic dysfunction
Study: NCT03349918

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Health Monitoring
Description: Use of mobile health application to monitor blood pressure and mood.
Study: NCT06520436

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic-Assisted Reduction
Description: The arthroscopic-assisted reduction was used as a one-stage operative treatment for all hips. In addition to that, Dega pelvic osteotomy and/or femoral shortening and varus derotation osteotomies were performed when necessary.
Study: NCT03807882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral M-ECT
Description: Following acute treatment with bilateral ECT of 6 sessions over a period of two weeks, Bilateral M-ECT will be administered at a frequency of 1 session/week for one month, then 1 session / 2 weeks for 2 months and then 1 session/month for next 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clozapine
Description: Clozapine will be given in accordance with Maudsley guideline: 12.5 mg on the first day, followed by 12.5mg twice daily on the second day, followed by 25mg twice daily for next two days and then increment of 25mg every two days till the target dose of 250-400 mg per day in two divided doses as per tolerability of the patients
Study: NCT03654898

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VITAL Start: Video-based pre-ART counseling
Description: Patients in the experimental group will receive VITAL start pre-ARV counseling (approximately 27 minutes video followed by 10 minute guided Q \& A to reinforce key messages and provide an opening for individual counseling=approximately total 37 minutes). This will be delivered by study staff.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Patients randomized to the control arm will receive the usual standard of care (SOC) pre ARV initiation education with the National ARV Educational Flipchart
Study: NCT03094806

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acapella Vibratory PEP Therapy Device plus usual care
Description: The acapella® Vibratory PEP Therapy System (PEP-FV) device is a handheld device that operates in same principle as standard FV. Unlike standard FV, it is not gravity dependent. It comes in two different devices to accommodate for different flows rates of the patient. It has similar properties of a standard FV and may be better tolerated.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Acapella Vibratory PEP Device plus usual care
Description: The Sham Acapella Vibratory PEP Device is the same as the Therapy Device, except the flutter valve has been removed from the device.
Study: NCT03578276

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pred-Gati-Brom
Description: The combination drop therapy containing prednisolone acetate 1%, gatifloxacin 0.5%, and bromfenac 0.075%
Study: NCT01098006

Intervention type: OTHER
Group type: OTHER
Intervention: Blood withdrawal
Description: A single blood sample was to be taken from all subjects at the study visit. No study-related treatment was given to the study participants.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood withdrawal
Description: A single blood sample was to be taken from all subjects at the study visit. No study-related treatment was given to the study participants.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood withdrawal
Description: A single blood sample was to be taken from all subjects at the study visit. No study-related treatment was given to the study participants.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood withdrawal
Description: A single blood sample was to be taken from all subjects at the study visit. No study-related treatment was given to the study participants.
Study: NCT01876173

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Decision Aid for an ICD (primary prevention, non-CRT)
Description: The intervention group will receive the PtDA, which provides a lay summary that outlines the facts, risks, benefits (including probabilities), specific to the option of an implantable defibrillator or the option of medical management to prepare them for consultation with the physician. Values are assessed to reveal which features of each option are important to patients.
Study: NCT03845348

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TD03
Description: Shampoo TD 3 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TD07
Description: Shampoo TD 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoconazole 2% Shampoo
Description: Ketoconazole 2% Shampoo
Study: NCT02806180

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual Operator Ultrasound Guided IV placement
Description: Second operator holds ultrasound probe.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Operator Ultrasound Guided IV placement
Description: Single operator holds ultrasound probe and places IV.